Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Appoints Dr Chris Bremer as Chief Executive Officer

Highlights:

- Dr Chris Bremer, MD, PhD, MBA, appointed as CEO effective 1 October 2026
- Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience spanning drug development, portfolio strategy, commercialisation and business development
- Career includes senior global executive roles at Grünenthal, including Executive Vice President, Early Products & Commercial Opportunities and Interim Chief Commercial Officer
- Extensive experience evaluating and executing licensing and strategic partnership transactions and guiding pharmaceutical assets from early development through to commercialisation
- During his career, Dr Bremer has executed on over US$1Bn in licensing transactions
- Appointment strengthens Neurizon's leadership as it advances NUZ-001 through late-stage clinical development and follows a comprehensive international executive search
- Dr Bremer will be based in Melbourne and will initially serve as Chief Executive Officer without appointment to the Company's Board

7 September 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Dr Chris Bremer, MD, PhD, MBA, as Chief Executive Officer, effective 1 October, 2026.

Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience spanning drug development, portfolio strategy, commercialisation and business development. He has extensive experience guiding pharmaceutical assets from early development through to product launch and lifecycle management, as well as evaluating and executing licensing and strategic partnership transactions.

His appointment comes as Neurizon advances NUZ-001 through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial and enters the important period leading up to topline results, expected in late Q2 CY2027. His combination of scientific, medical, commercial and transactional experience is particularly relevant as the Company prepares for the potential regulatory, development and strategic pathways that may follow and seeks to create long-term shareholder value.

The appointment follows a comprehensive international executive search conducted by the Board with Coulter Partners.

Interim Executive Chairman, Sergio Duchini said: "Chris joins Neurizon at an important point in the Company's development. With enrolment in Regimen I of the HEALEY ALS Platform Trial complete, our focus is on disciplined execution through to topline results, while ensuring Neurizon is appropriately positioned from a capital, regulatory and strategic perspective for what may follow.

"Chris distinguished himself through his combination of medical and scientific credibility, commercial and business development experience and senior international leadership. Importantly, he understands how to connect scientific and clinical development with commercial strategy, strategic partnering and long-term value creation.

"Chris has led large, diverse and internationally distributed teams, managed global portfolios and P&Ls, and contributed to significant pharmaceutical licensing, business development and commercialisation activities. He is also a highly respected leader who builds trust and communicates effectively across Boards, scientific and clinical teams, partners and investors.

"The Board is delighted to welcome Chris to Neurizon. We look forward to working with him as the Company advances NUZ-001 and seeks to create meaningful value for patients and shareholders."

Bringing Global Pharmaceutical and Biotechnology Leadership:

Dr Bremer spent approximately 20 years with Grünenthal, progressing through a series of increasingly senior commercial, strategic and global leadership roles.

His responsibilities included P&L leadership, global marketing and commercial strategy, product launches, portfolio strategy and global oversight of early products and commercial opportunities.

As Executive Vice President, Early Products & Commercial Opportunities, Dr Bremer led portfolio strategy across preclinical and clinical development and lifecycle management. He also co-chaired Grünenthal's integrated R&D–Commercial governance board, supporting the alignment of scientific development, portfolio investment and commercial strategy.

In this role, Dr Bremer was also responsible for the evaluation of internal development opportunities and contributed to the development and execution of in-licensing, out-licensing and business development strategies.

Dr Bremer subsequently served as Grünenthal's Interim Chief Commercial Officer, reporting to the company's CEO. He previously held senior commercial leadership roles across Europe, Latin America and other international markets. During this period, Dr Bremer has executed on over US$1Bn in licensing transactions.

Following his tenure at Grünenthal, Dr Bremer pursued senior leadership roles within entrepreneurial biotechnology companies. He has served as Chief Development Officer of Navigo Proteins, where he has been involved in the development strategy for precision oncology and radiotheranostics programs and in strategic collaborations with international pharmaceutical and biotechnology companies.

Dr Bremer was also the Founding Chief Executive Officer of GAIASO Theranostics, an Australian biotechnology company focused on radiopharmaceutical approaches in women's health, before transitioning to the role of Chief Business Officer.

Throughout his career, Dr Bremer has led organisations of up to 500 employees and worked extensively across geographically distributed and cross-functional teams.

Dr Bremer holds medical and doctoral qualifications and completed an MBA at INSEAD. Before his career in medicine and pharmaceuticals, he represented Germany as an elite swimmer at the 1992 Olympic Games, subsequently captaining the German National Swimming Team at the 1996 Olympic Games.

Incoming Chief Executive Officer, Dr Chris Bremer, commented: "I am honoured to join Neurizon at such an important point in the Company's development. I was attracted by the underlying science, the advanced clinical program for NUZ-001 and the opportunity to contribute to the development of a potential new treatment for people living with ALS.

"Throughout my career, I have worked at the intersection of scientific development, portfolio strategy, commercialisation and strategic partnering. Neurizon has established important clinical, regulatory, manufacturing and scientific progress, and I look forward to building on this work with the Board and the team.

"My immediate priorities will be to support disciplined execution of the clinical and regulatory program, maintain a strong focus on capital and organisational readiness, and prepare thoughtfully for the potential strategic pathways that may follow topline results.

"ALS has a profound impact on people living with ALS and their families, and I recognise the responsibility that comes with leading a company working in this area. I look forward to engaging with the ALS community, our shareholders, clinical collaborators, potential partners and the broader Australian biotechnology community."

Neurizon's next phase of growth:

Neurizon's lead investigational therapy, NUZ-001, is being evaluated in 250 participants in Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 2027.

The Company's priorities include disciplined execution of the clinical program through to topline results, continued regulatory and CMC readiness, further development of the scientific evidence supporting NUZ-001, and preparation for potential development, partnering and commercial pathways, subject to the outcomes of the study.

The Board believes Dr Bremer's experience integrating scientific and clinical development with commercial strategy, portfolio management and strategic partnering is closely aligned with these priorities.

Dr Bremer will be based in Melbourne and will work closely with Neurizon's Australian and US teams.

Following Dr Bremer's commencement, Mr Duchini will transition from Interim Executive Chair to Non-Executive Chair. Mr Duchini will work closely with Dr Bremer during the leadership transition.

Dr Bremer will initially be appointed as Chief Executive Officer and will not be appointed as a Director of Neurizon Therapeutics Limited.

The principal terms of his appointment are:

Term	Arrangement
Position	Chief Executive Officer
Commencement	1 October 2026
Location	Melbourne, Australia
Total Fixed Remuneration	A$450,000 per annum, inclusive of statutory superannuation
Short-Term Incentive	Target opportunity of 30% of Total Fixed Remuneration, with a maximum opportunity of 50%, subject to the achievement of Board-approved performance objectives
Long-Term Incentive	Target opportunity equivalent to 100% of Total Fixed Remuneration, proposed to comprise 70% performance rights and 30% options, subject to applicable performance conditions, Board approval and any required shareholder or regulatory approvals
Notice and termination	Either party may terminate without cause on 4 months written notice.

The incentive framework is intended to align Dr Bremer's remuneration with the creation of sustainable shareholder value. Performance measures are expected to include clinical and regulatory execution, capital management, strategic and business development outcomes, and leadership and governance performance.

Dr Bremer's appointment strengthens Neurizon's leadership as the Company advances NUZ-001 through late-stage clinical development. He joins at a defining point for the Company, bringing the scientific understanding, international leadership and commercial experience needed to guide Neurizon through its next phase and translate continued clinical execution into potential strategic, partnering and value-creation opportunities.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Marketing & Corporate Affairs
Lidija Damjanovic
Neurizon Therapeutics
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND). NUZ-001 is being evaluated as Regimen I in the registrational Phase 2/3 HEALEY ALS Platform Trial. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com